InspireMD (NYSE:NSPR) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the stock.

Several other brokerages have also recently commented on NSPR. Piper Sandler restated an “overweight” rating and set a $4.50 price objective on shares of InspireMD in a research note on Tuesday, September 17th. Lake Street Capital began coverage on shares of InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 target price for the company.

InspireMD Trading Down 0.4 %

NYSE:NSPR opened at $2.76 on Monday. The company has a market cap of $71.99 million, a PE ratio of -3.68 and a beta of 0.99. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.42. The company’s 50 day moving average is $2.77 and its two-hundred day moving average is $2.71.

InspireMD (NYSE:NSPR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The business had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same period in the previous year, the business posted ($0.15) EPS. As a group, analysts expect that InspireMD will post -0.79 EPS for the current fiscal year.

Hedge Funds Weigh In On InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC bought a new position in shares of InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned approximately 0.74% of InspireMD as of its most recent SEC filing. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.